Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, ...

The actress and cancer survivor Lisa Ray opens up about entering menopause at 37 during her battle with multiple myeloma.

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Exicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...

In a heartfelt Instagram post, actress Lisa Ray discusses her battle with chemotherapy-induced menopause at 37, encouraging ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, explains J&J’s ...

IGI reported that it has recently wrapped up the dose-escalation phase of its Phase 1 clinical trial involving patients with ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to attack cancer.

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term ...